Shots:

• Evotec to receive upfront- up to $170M pre/clinical & commercial milestones per program with royalties on sales of products. Takeda to get access to utilize Evotec’s platform to discover at least five drug discovery programs with an aim to deliver Evotec’s clinical candidates to Takeda for pursuing its clinical development
• The collaboration will unite Evotec’s drug discovery program with Takeda’s development and commercialization expertise and its transformative therapeutic approaches in oncology- gastroenterology- neuroscience and rare diseases
• Evotec will leverage its drug discovery platform to validate therapeutic hypotheses and advance small molecule programs- providing Takeda an option to assume responsibility at Evotec’s lead series and preclinical candidates

Click here to­ read full press release/ article 

Ref: Evotec | Image: Takeda